777 replies to this topic

[ImmInst]

BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Business Wire (press release) - 2 hours ago

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and provided a ...

View the full article

[ImmInst]

BioTime, Inc. (BTX) Posts Quarterly Earnings Results, Misses Expectations By ...
Washington News Wire - 3 hours ago

BioTime logo BioTime, Inc. (NYSEMKT:BTX) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.05, ARN reports.

BioTime, Inc. (BTX) Releases Earnings Results, Misses Estimates By $0.05 EPS - NewsWay 21

View the full article

[ImmInst]

BRIEF-Biotime Inc Qtrly loss per common share $0.19
Reuters - May 10, 2016

May 10 Biotime Inc. * Qtrly loss per common share $0.19. * Q1 earnings per share view $-0.14, revenue view $1.4 million -- Thomson Reuters I/B/E/S.

View the full article

[ImmInst]

BioTime Inc (BTX) Drops 6.94% on May 11
Equities.com - 6 hours ago

BioTime Inc (BTX) was one of the Russell 2000's biggest losers for Wednesday May 11 as the stock slid 6.94% to $2.68, a loss of $-0.2 per share.

View the full article

[ImmInst]

Biotime Inc (CVE:ATW) Institutional Investor Sentiment Is 1.08
Wall Street Hints and News - 9 hours ago

Biotime Inc (CVE:ATW) institutional sentiment increased to 1.08 in Q4 2015. Its up 0.43, from 0.65 in 2015Q3. The ratio is positive, as 27 active investment managers opened new and increased stock positions, while 25 decreased and sold holdings in ...

View the full article

[ImmInst]

Stock on Downward Trajectory: BioTime, Inc. (:BTX)
Franklin Independent - 16 minutes ago

BioTime, Inc. (:BTX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -13.13% for the month and -3.73% over the past five trading days.

View the full article

[ImmInst]

Stock on Downward Trajectory: BioTime, Inc. (:BTX)
Franklin Independent - 3 hours ago

BioTime, Inc. (:BTX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -13.13% for the month and -3.73% over the past five trading days.

View the full article

[ImmInst]

Stock on Downward Trajectory: BioTime, Inc. (:BTX)
Franklin Independent - 7 hours ago

BioTime, Inc. (:BTX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -13.13% for the month and -3.73% over the past five trading days.

View the full article

[ImmInst]

Stock on Downward Trajectory: BioTime, Inc. (:BTX)
Franklin Independent - 21 hours ago

BioTime, Inc. (:BTX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -13.13% for the month and -3.73% over the past five trading days.

View the full article

[ImmInst]

Stock on Downward Trajectory: BioTime, Inc. (:BTX)
Franklin Independent - May 15, 2016

BioTime, Inc. (:BTX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -13.13% for the month and -3.73% over the past five trading days.

View the full article

[ImmInst]

BioTime Inc (BTX) is Trading Lower on Unusual Volume for May 17
Equities.com - 2 hours ago

BioTime Inc (BTX) experienced unusually high volume on May. 17, as the stock lost 2.33% to a closing price of $2.52. The stock saw 315,290 shares trade hands over the course of the day on 1,244 trades.

View the full article

[ImmInst]

BioTime Inc (BTX) is Trading Lower on Unusual Volume for May 17
Equities.com - 5 hours ago

BioTime Inc (BTX) experienced unusually high volume on May. 17, as the stock lost 2.33% to a closing price of $2.52. The stock saw 315,290 shares trade hands over the course of the day on 1,244 trades.

View the full article

[ImmInst]

BioTime Inc (BTX) is Trading Lower on Unusual Volume for May 17
Equities.com - 9 hours ago

BioTime Inc (BTX) experienced unusually high volume on May. 17, as the stock lost 2.33% to a closing price of $2.52. The stock saw 315,290 shares trade hands over the course of the day on 1,244 trades.

Biotime Incorporated (NYSEMKT:BTX) Sellers Increased By 1.16% Their Shorts - Franklin Independent

View the full article

[ImmInst]

BioTime Inc (BTX) is Trading Lower on Unusual Volume for May 17
Equities.com - 12 hours ago

BioTime Inc (BTX) experienced unusually high volume on May. 17, as the stock lost 2.33% to a closing price of $2.52. The stock saw 315,290 shares trade hands over the course of the day on 1,244 trades.

Biotime Incorporated (NYSEMKT:BTX) Sellers Increased By 1.16% Their Shorts - Franklin Independent

View the full article

[ImmInst]

Stock Heading South Today: BioTime, Inc. (:BTX)
The Post - 19 minutes ago

BioTime, Inc. (:BTX) was a top loser in today's session as the company saw shares drop -6.54% on the day at the time of writing.

View the full article

[ImmInst]

Stock Seeing Gains in Session: BioTime, Inc. (:BTX)
The Post - 1 hour ago

Shares of BioTime, Inc. (:BTX) are pushing higher in today's trading session. At the time of writing, the stock had hit $2.64.

View the full article

[ImmInst]

Volatile Stock Watch: BioTime, Inc. (:BTX)
Franklin Independent - 2 hours ago

BioTime, Inc. (:BTX)'s shares are highly volatile in today's session as the stock moved 5.99%, clocking in at $2.66 with a recent bid.

View the full article

[ImmInst]

Volatile Stock Watch: BioTime, Inc. (:BTX)
Franklin Independent - 9 hours ago

BioTime, Inc. (:BTX)'s shares are highly volatile in today's session as the stock moved 5.99%, clocking in at $2.66 with a recent bid.

View the full article

[ImmInst]

Moving Stocks: BioTime, Inc. (NYSEMKT:BTX), BioCryst Pharmaceuticals, Inc ...
Benchmark Monitor - 14 hours ago

BioTime, Inc. (NYSEMKT:BTX) reported financial results for the first quarter ended March 31, 2016 and provided a corporate update.

View the full article

[ImmInst]

Is it Time to Cash in Profits on BioTime, Inc. (:BTX)
Franklin Independent - 3 hours ago

BioTime, Inc. (:BTX) stock has moved in an upward direction over the past week, yielding nice gains for investors. Based on the recent close, the shares are up 6.59% over the past five trading days.

View the full article

[ImmInst]

Could BioTime, Inc. Decline After Today's Huge Increase?
Wall Street Hints and News - 3 hours ago

The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! The stock increased 9.56% or $0.24 on May 20, hitting $2.75.

View the full article

[ImmInst]

BioTime Inc.: Asterias Biotherapeutics Announces Positive New Long-Term Follow ...
The Wall Street Transcript - May 24, 2016

FREMONT, Calif., May 24, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced new ...

Asterias Biotherapeutics Gains 7% on Positive Long-Term Data on AST-OPC1 in ... - Sonoran Weekly Review
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy ... - Benzinga

View the full article

[ImmInst]

BioTime Inc. (BTX) is Trading Higher on Unusual Volume for June 08
Equities.com - 6 hours ago

BioTime Inc. (BTX) experienced unusually high volume on Jun. 08, as the stock gained 2.13% to a closing price of $2.88. The stock saw 225,297 shares trade hands over the course of the day on 1,238 trades.

View the full article

[ImmInst]

BioTime Inc. (BTX) is Trading Higher on Unusual Volume for June 08
Equities.com - 13 hours ago

BioTime Inc. (BTX) experienced unusually high volume on Jun. 08, as the stock gained 2.13% to a closing price of $2.88. The stock saw 225,297 shares trade hands over the course of the day on 1,238 trades.

View the full article

[ImmInst]

Biotime to up dosage for OpRegen in phase I/II trial
Proactive Investors USA & Canada - 2 hours ago

BioTime Inc. (NYSE MKT:BTX) and Cell Cure Neurosciences Ltd have received approval to move to the second cohort of patients in the Phase I/IIa clinical trial of eye drug OpRegen.

BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start ... - Business Wire (press release)

View the full article

[ImmInst]

Share Volatility Review: BioTime, Inc. (:BTX)
Franklin Independent - 3 hours ago

BioTime, Inc. (:BTX)'s shares are highly volatile in today's session as the stock moved 2.19%, clocking in at $2.80 with a recent bid.

View the full article

[ImmInst]

BioTime, Inc. Announces Proposed Public Offering of Common Stock
Business Wire (press release) - 10 minutes ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares ...

View the full article

[ImmInst]

BioTime, Inc. Announces Proposed Public Offering of Common Stock
Business Wire (press release) - 3 hours ago

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares ...

View the full article

[ImmInst]

BioTime, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire (press release) - 3 minutes ago

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of ...

View the full article

[ImmInst]

BioTime, Inc. Announces Pricing of Public Offering of Common Stock
Business Wire (press release) - 3 hours ago

BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of ...

BioTime Launching Public Offering - Genetic Engineering & Biotechnology News

View the full article